Genomics: Hepatitis C virus gets personal

@article{Iadonato2009GenomicsHC,
  title={Genomics: Hepatitis C virus gets personal},
  author={Shawn Iadonato and Michael G. Katze},
  journal={Nature},
  year={2009},
  volume={461},
  pages={357-358}
}
Many people infected with the hepatitis C virus are not cured despite gruelling therapy. A human genetic variant that predicts successful treatment has been identified. So is personalized therapy now a possibility? 
Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population
  • Wanyu Li, Yanfang Jiang, J. Niu
  • Medicine, Biology
    Liver international : official journal of the International Association for the Study of the Liver
  • 2011
TLDR
It is found that genetic polymorphisms near the IL28B gene are strongly associated with sustained viral response and spontaneous viral clearance in chronically infected hepatitis C patients.
YKL‐40‐gene polymorphism affects acute cellular rejection and fibrosis progression after transplantation for hepatitis C virus‐induced liver disease
TLDR
The aim of this study was to determine the prevalence of YKL‐40‐gene polymorphism in hepatitis C virus (HCV)‐positive patients and its impact on the incidence of acute cellular rejection, graft fibrosis and antiviral treatment response.
Liver transplantation and hepatitis C: Will understanding the interleukin‐28B polymorphisms improve outcomes?
  • G. McCaughan, N. Shackel, D. Bowen
  • Biology
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 2011
The prediction of treatment outcomes for patients with chronic hepatitis C virus (HCV) infection has been revolutionized by the finding of a strong association between single-nucleotide polymorphisms
Interleukin 28B Polymorphisms and Hepatitis C-Translating the Association into Clinical Decision Making.
  • C. Puri
  • Biology, Medicine
    Journal of clinical and experimental hepatology
  • 2011
Impact of IL-28B polymorphism on outcome in patients with hepatitis C after liver transplantation
  • U. Neumann
  • Medicine, Biology
    Expert review of gastroenterology & hepatology
  • 2011
TLDR
Significant variations in graft inflammation and fibrosis, susceptibility to HCV infection, spontaneous viral clearance and antiviral therapy response suggest the existence of endogenous factors that influence the evolution of graft disease after LT, and they suggest the influence of multiple genes in nontransplant patients.
The Impact of Host Factors on Management of Hepatitis C Virus
TLDR
Host factors that are responsible for responsiveness to HCV therapy with Peg-IFN-α/RBV include host genetic factors, age, ethnicity, gender, cirrhosis, weight, steatosis, insulin resistance, and type 2 diabetes mellitus.
HCV-Recurrence After Liver Transplantation
Hepatitis-C-virus (HCV) represents one of the most serious threats for human liver and chronic HCV-infection results in the development of liver cirrhosis and hepatocellular carcinoma (HCC). HCV is
Genetic Variants of STAT-4 Affect the Development of Graft Fibrosis After Liver Transplantation for HCV-Induced Liver Disease
TLDR
Present results indicate a possible impact of genetic confounders in the recipient on graft fibrogenesis, thus explaining significantly different graft behavior observed after transplantation for HCV-associated liver disease.
Association of mannose‐binding lectin‐2 gene polymorphism with the development of hepatitis C‐induced hepatocellular carcinoma
  • D. Eurich, S. Boas-Knoop, D. Seehofer
  • Medicine, Biology
    Liver international : official journal of the International Association for the Study of the Liver
  • 2011
TLDR
The aim of this study was to determine the prevalence of MBL‐2 polymorphism in hepatitis C virus (HCV)‐induced hepatocellular carcinoma (HCC) based on histological analysis of explanted livers in patients undergoing liver transplantation (LT).
Role of mannose‐binding lectin‐2 polymorphism in the development of acute cellular rejection after transplantation for hepatitis C virus‐induced liver disease
TLDR
The role of MBL‐2 genotypes after liver transplantation for hepatitis C virus (HCV)‐induced liver disease regarding the incidence of acute cellular rejection, graft inflammation, fibrosis development, and antiviral treatment response is elucidated.
...
1
2
3
4
...

References

SHOWING 1-10 OF 10 REFERENCES
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
TLDR
It is reported that a genetic polymorphism near the IL28B gene, encoding interferon-λ-3 (IFN-α-2a) is associated with an approximately twofold change in response to treatment, both among patients of European ancestry and African-Americans.
IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
TLDR
The data suggest that host genetics may be useful for the prediction of drug response, and they also support the investigation of the role of IL28B in the treatment of HCV and in other diseases treated with IFN-α.
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
TLDR
It is shown that the C/C genotype strongly enhances resolution of HCV infection among individuals of both European and African ancestry, the strongest and most significant genetic effect associated with natural clearance ofHCV.
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.
TLDR
AA with chronic hepatitis C genotype 1 have lower rates of virologic response to peginterferon and ribavirin than CA, and these differences are not explained by disease characteristics, baseline viral levels, or amount of medication taken.
Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C
TLDR
A genome-wide association study to null virological response (NVR) in the treatment of patients with hepatitis C virus (HCV) genotype 1 within a Japanese population is reported.
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1
TLDR
Results provide proof of concept that CCR5 antagonism is a viable antiretroviral therapeutic approach for HIV-1-positive individuals prescreened for the absence of CXCR4-using virus.
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.
TLDR
In patients infected with HCV genotype 1, the rates of sustained virologic response and tolerability did not differ significantly between theTwo available peginterferon-ribavirin regimens or between the two doses of pegin terferon alfa-2b.
Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.
TLDR
A deletion of three base pairs that results in the omission of a phenylalanine residue at the center of the first predicted nucleotide-binding domain was detected in CF patients.
A haplotype map of the human genome
TLDR
A public database of common variation in the human genome: more than one million single nucleotide polymorphisms for which accurate and complete genotypes have been obtained in 269 DNA samples from four populations, including ten 500-kilobase regions in which essentially all information about common DNA variation has been extracted.
IL-28, IL-29 and their class II cytokine receptor IL-28R
TLDR
A family of three cytokines, designated interleukin 28A, IL-28B and IL-29, that are distantly related to type I interferons (IFNs) and the IL-10 family are identified and may serve as an alternative totype I IFNs in providing immunity to viral infection.